Collection of blood samples from patients with metastatic digestive cancers
Official title: Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT03978078 · Data updated 2026-11-12
This study is collecting blood samples from patients with advanced digestive cancers to see if they can help create better, personalized treatment plans.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy, trastuzumab |
| Locations | 1 site (Montpellier, Hérault) |
| Status | Recruiting |
| Started | September 12, 2016 |
| Main results expected | September 2026 |
| Study ends | September 2031 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT03978078 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed adenocarcinoma of the digestive system who are about to begin first or second line metastatic chemotherapy or targeted therapy.
✕Probably not a fit
Patients who are under 18 years old, have non-adenocarcinoma histological types, or are currently receiving specific treatments in the metastatic lines may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a comprehensive collection of blood samples from patients diagnosed with metastatic digestive adenocarcinoma, specifically during their first and second lines of chemotherapy and/or targeted therapy. The samples will be utilized for research projects focused on developing personalized management strategies for these patients. The study addresses the current limitations in identifying biomarkers that can predict treatment responses and monitor efficacy, which are crucial for improving patient outcomes. By collecting samples before and during treatment, the research seeks to enhance understanding of resistance mechanisms and treatment effectiveness.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with metastatic digestive cancers.
How similar studies have gone: Other studies have shown promise in utilizing biological samples for developing targeted therapies, indicating that this approach has potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female ≥ 18 years old 2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus 3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy 4. Informed consent form (ICF) signed Exclusion Criteria: 1. Male or female \< 18 years old 2. Non-adenocarcinoma histological type 3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line 4. Pregnant and/or breastfeeding woman 5. Patient not affiliated to a social security system 6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons 7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples
Where it's running
-
Institut régional du cancer de Montpellier
Montpellier, Hérault, France Recruiting
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: jean-pierre.bleuse@icm.unicancer.fr
- Phone: 4 67 61 31 02
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Imaging method for digestive system cancer using targeted PET scans
This study is testing a new type of PET scan to see if it can better help doctors find and diagnose cancers in the digestive system.
-
Registry for patients with unresectable pancreatic cancer treated with OncoSil™
This study is testing how well the OncoSil™ device works and its safety for people with advanced pancreatic cancer who are also receiving chemotherapy.
-
Vasodilator Therapy to Reduce Vascular Side Effects in GI Cancer Patients on Fluoropyrimidines
This study tests whether vasodilator drugs (isossorbide mononitrate or diltiazem) or placebo can reduce blood vessel toxicity for adults with gastrointestinal cancers treated with fluoropyrimidine chemotherapy.
-
Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays
This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.
-
Using fucoidan to prevent fatigue in cancer patients undergoing chemotherapy
This study tests if a seaweed supplement called fucoidan can help cancer patients undergoing chemotherapy feel less tired.
-
Understanding risk factors and genetic changes in biliary tree cancers
This study is trying to find out what causes biliary tree cancers and how genetic changes can help doctors understand treatment responses in patients with these cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.